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Abstract
Background
Polygenic obesity in Solid Organ Transplant (SOT) populations is considered a risk factor for
the development of metabolic abnormalities and graft survival. Few studies to date have studied
the genetics of weight gain in SOT recipients. We aimed to determine whether weighted genetic
risk scores (w-GRS) integrating genetic polymorphisms from GWAS studies (SNP group#1
and SNP group#2) and from Candidate Gene studies (SNP group#3) influence BMI in SOT
populations and if they predict10% weight gain (WG) one year after transplantation. To do
so, two samples (nA = 995, nB = 156) were obtained from naturalistic studies and three w-GRS
were constructed and tested for association with BMI over time. Prediction of 10% WG at one
year after transplantation was assessed with models containing genetic and clinical factors.
Results
w-GRS were associated with BMI in sample A and B combined (BMI increased by 0.14 and
0.11 units per additional risk allele in SNP group#1 and #2, respectively, p-values<0.008).
w-GRS of SNP group#3 showed an effect of 0.01 kg/m2 per additional risk allele when com-
bining sample A and B (p-value 0.04). Models with genetic factors performed better than
models without in predicting 10% WG at one year after transplantation.
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Conclusions
This is the first study in SOT evaluating extensively the association of w-GRS with BMI and
the influence of clinical and genetic factors on 10% of WG one year after transplantation,
showing the importance of integrating genetic factors in the final model. Genetics of obesity
among SOT recipients remains an important issue and can contribute to treatment person-
alization and prediction of WG after transplantation.
Introduction
Obesity has become a worldwide major concern since it has more than doubled in the last
decades. In 2014, 39% of adults were overweight (25 kg/m2 BodyMass Index (BMI)< 30 kg/
m2) and 13% were obese (BMI 30 kg/m2) [1]. Obesity is a risk factor leading to other co-
morbidities such as diabetes, cardiovascular diseases and certain type of cancers [1]. Among
solid organ transplant (SOT) recipients, the rate of overweight and obesity has increased over
the past years. By 2011, 34% of liver transplant candidates were obese, compared to 29% in
2001 [2]. Similar results have been found for kidney, heart and lung transplant recipients [3–
5]. Although overweight and obesity prevalence are similar to those measured in general popu-
lation studies, in SOT recipients the consequences are more serious. Indeed, obesity in SOT is
an important risk factor for the development of New Onset Diabetes after Transplant
(NODAT) [6] which has a deleterious effect on graft survival [7, 8]. Moreover, it can be often
associated with delayed graft function related to surgical and post-operative complications [9].
Few longitudinal studies examining weight gain (WG) among transplant recipients have
been conducted to date, most of them focusing onWG during the first year post transplanta-
tion. AWG ranging from 3.5 to 10 Kg has been reported in heart, liver and kidney transplant
recipients [10–14] and a mean of 10%WG during the first year after transplantation was
described in kidney transplant recipients [15]. A threshold of 10% increase of ideal body
weight, defined as the metropolitan relative weight criteria [16], has been related to a risk of
developing cardiovascular disease in general populations followed for more than 25 years [16,
17]. Ethnicity, sex, age in addition to specific factors such as transplanted organ, glucocorti-
coids and immunosuppressive treatments are some of the described factors influencingWG
following SOT and NODAT [18], as well as genetic factors. Most studies on transplant popula-
tions focusedmainly on the NODAT rather thanWG [19, 20]. Regarding BMI-related pheno-
types, a protocol for the first systematic literature review has been published. The aim is to
condense and compare the current state of evidence onWG, overweight and obesity in SOT
individuals including genetic and non-genetic factors [21]. Regarding candidate gene
approach, two single nucleotide polymorphisms (SNPs) and one insertion/deletionhave previ-
ously been associated with BMI-related phenotypes [22–24]. These studies were conducted in
three heterogeneous populations with small or moderate sample sizes (n<270), with different
obesity-related outcomes and type of transplanted organ. Furthermore, different polymor-
phisms were analyzed. To our knowledge, no GenomeWide Association Studies (GWAS)
investigating BMI variants within SOT recipients have yet been published. Recently, a microar-
ray study examining gene expression in subcutaneous adipose tissue in kidney transplant recip-
ients found that the expression of obesity-related genes was correlated with weight change
[25]. The top 41 ranked genes were further associated with obesity through a text mining
approach [26], including genes related to diabetes, obesity and neurological concepts such as
dopamine, nicotine, and cognition [25]. Interestingly, two of these genes (i.e.MTCH2 and
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TFAP2B) were also found in the largest BMI GWAS meta-analysis conducted to date in the
general population [27]. This meta-analysis was conducted in more than 300 000 individuals
and reported 97 SNPs associated with BMI, also including 32 previously replicated BMI SNPs
[28–31]. All 97 polymorphisms explained up to 2.7% of BMI variability within these individu-
als [27]. Since polygenic or common obesity is influenced by many genetic polymorphisms,
genetic risk scores (GRS) provide a useful tool summarizing risk-associated variations across
the genome by aggregating information frommultiple-risk SNPs, and they may improve the
consistency and the power to determine genetic risk in polygenic diseases [32, 33].
In the present study, we aimed to study the association of three weighted GRS, integrating
previously published SNPs, with BMI in two cohorts of Swiss transplanted individuals. In addi-
tion, we assessed whether these genetic polymorphisms could predict a10%WG during the
first year post transplant.
Materials and Methods
Sample A
The Swiss transplant cohort study (STCS) is an ongoing prospectivemulticenter study (Basel,
Bern, Geneva, Lausanne, St. Gallen and Zurich) started in May 2008 which enrolls SOT recipi-
ents with no particular eligibility or exclusion criteria other than having received an allotrans-
plant and having signed the informed consent [34]. The present study (May 2008–May 2011)
included SOT recipients (i.e. kidney, liver, lung, heart, or multi-organ) with a functional graft
for at least 12 months after transplantation in order to have a sufficient period of follow-up (A
total of 1294 patients were followed up in their respective transplant centers at baseline and at
6, 12, 24, 36 and 48 months after transplantation. Lipid profile, BMI, blood pressure and
patient characteristics were collected at the different time-points of the follow up. Further
details have been published elsewhere [34, 35]. Only Caucasians and Recipients of 18 years or
older were retained. If an individual was subjected to more than one transplant, only the first
SOT was considered. A total of 995 patients were considered for analysis.
Sample B
A total of 197 SOT recipients (i.e. lung, liver and kidney) were enrolled between 2003 and 2005
from the outpatient clinic of the transplant center of the University Hospital of Lausanne, Swit-
zerland. Only patients with a functional graft for more than 12 months were eligible to partici-
pate in the study. Further details can be found elsewhere [35–37]. Briefly, data regarding
patients’ age, gender, BMI, ethnicity, immunosuppressive treatments among others were col-
lected retrospectively from the medical files. Additionally, data concerning weight, at baseline,
at 1, 3, 6, 9, 12 and at the yearly follow-up during the 5 years after transplantation were col-
lected retrospectively from the medical files betweenOctober 2011 and April 2012. Blood sam-
ples were collected for further genotyping analysis. 156 individuals of 18 years or older for
whom Caucasian ethnicity was reported and had clinical data available, were included in the
analysis. This sample was considered as a replication sample.
All patients gave their written informed consent and the studies were approved by the ethics
committee of the Lausanne and Geneva University Hospitals.
Genotype selection and genotyping
SNP selectionwas done according to large Meta analyses of GWAS published on BMI. SNP
group#1 included 32 BMI associated polymorphisms in general adult populations [28]. A sec-
ond group consisted of 97 SNPs (SNP group#2) recently associated with BMI in general
GRS and Weight Gain in Transplant Populations
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populations and which included the previous 32 SNPs (or its proxies) [27]. Only SNPs signifi-
cant at GWAS levels (i.e. p-value< 5x10-8) were retained for the analysis. S1 and S2 Tables
show a detailed description of the selected SNPs.
Additionally, 41 genes whose expression in subcutaneous adipose tissue has been previously
associated with weight change in kidney transplant recipients [25] were included. A selection
of tagging SNPs of these genes was obtained using HapMap Genome Browser (release 28). In
order to avoid over representation of a particular gene, one tagging SNP per gene was selected
based on the number of SNPs tagged and on the genotype availability in our samples. Six genes
were excluded since no tagging SNPs were found in HapMap. Of note, two genes (i.e.MTCH2,
TFAP2B) were also present in the GWAS mentioned previously (SNP group#1). Finally 19
SNPs, for which genotype was available in both samples A and B, were retained in the SNP
group#3. A detailed description of these genes and polymorphisms can be found in S3 Table.
For the sample A, genotypes were analyzed with the Human OmniExpress-24 BeadChipKit
as describedby the manufacturer’s protocol (Illumina, San Diego, CA). For the sample B, geno-
typing was performed using the Illumina 200K Cardiometabochip (Illumina, San Diego, CA).
Briefly, the CardioMetabochip is a custom Illumina iSelect genotyping array designed to test
DNA variation of 200’000 SNPs from regions identified by large scale meta-analyses of genome
wide association studies (GWAS) for metabolic and cardiovascular traits [38]. Polymorphisms
or proxies were chosen based on genotype availability. A Quality Control was done for the gen-
otyped SNPs. Samples were excluded from the analysis if sex was inconsistent with genetic data
from X-linkedmarkers, and when genotype call rate was<0.96 and gene call score<0.15. Gen-
omeStudio Data Analysis Software was used to export results generated by Illumina
CardiometaboChip.
Construction of Genetic Risk Scores
Three GRS were built following a weighted GRS (w-GRS)method as previously described [28]
with 32 SNPs (SNP group#1) and 97 SNPs (SNP group#2) both from GWAS, and 19 SNPs
(SNP group#3) from candidate genes. Briefly, genotypes from each SNP were coded as 0, 1 or 2
according to the number of BMI risk alleles and each polymorphismwas then weighted by its
β-coefficient (allele effect) based on the assumption that all SNP of interest have independent
effects and contribute in an additive manner on BMI. In order to facilitate interpretation, the
GRS was subsequently rescaled as previously described [39]. Thus, each unit increase in the
GRS corresponded approximately to one additional risk allele. Allele effects on BMI were
obtained from those published in the literature for the SNPs group#1 and #2 [27, 28]. For the
SNP group#3 allele effects were calculated from a large population based sample, GIANT,
which consisted in a meta-analysis of GWAS with a discovery set of 123,865 individuals of
European ancestry from 46 studies for height [40], BMI [28] and waist-to-hip ratio [41].
Statistical analysis
Descriptive analysis of quantitative data is presented as median and range unless otherwise
specifiedwhereas qualitative data is expressed as percentages. Chi-squared test or rank sum
test were used for association studies within categorical data or non-parametric continuous
variables, respectively. Hardy-Weinberg Equilibrium (HWE) was determined for each poly-
morphism by a chi-square test. P-value threshold was set at <0.05 and Bonferronimultiple test
correctionwas applied when necessary (i.e. 0.05/6; 2 tests of w-GRS in the whole sample A and
2 tests of w-GRS in two different subgroups). Due to the exploratory nature of the analysis con-
ducted for the third GRS, in the present work we did not consider multiple test correction for
this GRS.
GRS and Weight Gain in Transplant Populations
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For multivariate analysis, a GeneralizedAdditive MixedModel (GAMM) was used to deal
with complex and non-linear BMI evolution at different time points and presence of multiple
observations per individual introducing interdependence among observations.A random effect
at the subject level was also introduced to take the dependence structure of observeddata into
account. The GAMMs were fitted using the mgcv package of R (settings were fixed at package
defaults). To bemore conservative, the uncertainty of estimated parameters was assessed by
1’000 bootstraps on individuals [42]. Multivariate models were adjusted by gender, type of
treatment, organ, living donor and CMV as previously described in the literature [18], as well
as genetic factors and time of follow-up. Because sex and age have been described as factors
influencingWG [15], further analyses were conducted stratifying by gender and the median
age when the interactions with w-GRS were significant.
Prediction of10% WG one year after transplantation in the sample A
A binary logistic regression model at 12 months after transplant was used to determine
whether clinical and genetic factors influence a10%WG one year after transplantation for
those cases where genetic components were significantly associated with BMI. The ability to
discriminate between gainers of 10% weight versus those who did not gain 10% one year after
transplantation was assessed with the Area Under the Receiver Operating Characteristic Curve
(AUROC) for a model containing only clinical covariates (i.e. age, sex, transplanted organ,
BMI at baseline, immunosuppressant treatment) and another model integrating clinical and
genetic factors. For each pair of models compared (i.e. the non-genetic nested in its corre-
sponding genetic model) the same number of individuals must be tested in order to be compa-
rable. In addition, Sensitivity (percentage of correctly predicted individuals with10%WG
among all individuals with10%WG), Specificity (percentage of correctly predicted individu-
als with<10%WG among all truly individuals with<10%WG) and Accuracy (percentage of
correctly classified gainers of10% weight among all subjects) were obtained for each model
using “pROC” R package [43]. An AUROC lower than 0.70 indicates low discriminative accu-
racy [44]. As previously described, [45, 46] in order to assess the added value of selected SNPs
in predicting a10%WG one year after transplantation (i.e. comparison of genetic and non-
genetic models), likelihood ratio tests (LRT) and Integrated Discrimination Improvement
(IDI) estimates with their respective p-values were calculated. Finally, the number needed to
genotype (NNG) (i.e. the average number of patients who need to be genotyped to detect one
misclassified case of10%WG one year after transplantation if using only clinical covariates)
was calculated based on the inverse of the difference between the accuracy of clinical and
genetic models [47].
Results
Population description
The characteristics of sample A are presented in Table 1. Sixty-six percent were men, 17.0%
were obese one year after transplantation and 27.1% were diagnosed of NODAT. Similar pat-
terns (p>0.05) were observed in sample B (60.9%, 18.5% and 28.8%, respectively, Table 2).
Twenty three percent of individuals in sample A gained10% of weight the first year after
transplantation and 35% of individuals in sample B (p<0.001). The mean of WG one year after
transplantation was 3.5% and 6.3% for samples A and B, respectively. Sample A included also
heart and multi-organ transplant, individuals were older than in sample B (median age: 54
years compared to 48, p<0.001) and there was a high prevalence of living donors (27.1% and
11.5%, respectively, p<0.001). Tacrolimus (TAC) was more frequently prescribed in sample A,
whereas cyclosporine (CSA) was more used in sample B (45.1% versus 34.6%, respectively for
GRS and Weight Gain in Transplant Populations
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TAC and 19.6% versus 65.4%, respectively for CSA; p<0.05). For sample A, individuals with at
least 3 immunosuppressive treatments (i.e. cyclosporine, tacrolimus, glucocorticoids, azatiopr-
ine and/or mycophenolate) gained significantlymore weight at one year after transplantation
compared to the others (p = 0.01, Fig 1). Of note, 99% of those with at least 3 immunosuppres-
sants had a glucocorticoid treatment prescribed, possibly contributing to this weight gain. No
Table 1. Characteristics of Sample A (all and by 10% weight gain one year after transplantation).
Characteristic All wg10%* wg<10%* p-value #
n = 995 n = 204 n = 673
Recipient age at transplantation (years), median (range) 54 (18–79) 51 (18–73) 55 (18–79) 0.0001
Recipient men (%) 66.0 56.8 68.9 0.001
Period of follow up (months), median (range) 12 (0–48) 12 (0–48) 12 (0–48) 0.55
Living donor (%) 27.1 27.9 29.6 0.6
Donor age (years), median (range) 53 (1–86) 50 (1–80) 53 (1–86) 0.04
Transplanted organ (%)
Kidney 62.4 61.3 67.2 <0.001
Liver 15.9 10.3 14.7
Lung 9.5 14.7 7.8
Heart 6.5 11.3 4.6
Multi-organ transplantation 4.1 2.5 4.5
Before transplant
BMI (kg/m2), median (range) 24.6 (13.7–41.2) 23.1 (14.9–37.4) 24.9 (14.3–41.2) 0.0001
Overweight (25 kg/m2 BMI >30 kg/m2), % 30.7 23.0 32.5 <0.001
Obese (BMI 30 kg/m2), % 15.3 9.3 16.8
HDL (mmol/L), median (range) 1.2 (0.01–8) 1.2 (0.1–4.1) 1.2 (0.09–8) 0.7
LDL (mmol/L), median (range) 2.2 (0.06–10.02) 2.2 (0.1–7.1) 2.2 (0.08–10.0) 0.3
Cholesterol (mmol/L), median (range) 4.2 (0.3–11.7) 4.0 (0.3–9.9) 4.2 (0.8–11.7) 0.2
At 12 months after transplant
BMI (kg/m2), median (range) 25.2 (15.3–44.6) 27.1 (18.8–44.6) 24.7 (15.3–44.3) 0.0001
Overweight (25 kg/m2 BMI >30 kg/m2), % 34.7 39.0 33.0 <0.001
Obese (BMI 30 kg/m2), % 17.0 27.0 14.0
HDL (mmol/L), median (range) 3.5 1.3 (0.5–4.1) 1.3 (0.2–7.0) 0.08
LDL (mmol/L), median (range) 1.3 (0.21–7) 2.6 (0.8–5.8) 2.6 (0.3–8.7) 0.8
Cholesterol (mmol/L), median (range) 2.6 (0.3–8.7) 5.0 (2.3–9.2) 4.8 (1.7–12.0) 0.01
Incidence of NODAT (%)$ 27.1 25.9 28.1 0.6
CMV serostatus (%)
Recipient CMV infection (R+) 57.1 21.8 23.7 0.9
Donor CMV infection (D+) 53.0 20.8 20.6
Recipient and Donor CMV infection (R+D+) 32.6 33.2 33.1
Calcineurin inhibitors (%)
TAC 45.1 42.2 48.6 0.3
CSA 19.6 21.1 19.6
None 35.2 36.8 31.8
wg: weight gain, CMV: Cytomegalovirus, TAC: Tacrolimus, CSA: Cyclosporine, NODAT: New Onset Diabetes After Transplant
# comparison between wg10% and wg<10%
*at 12 months after transplantation, missing n = 118
$NODAT was diagnosed if patients were taking an antidiabetic treatment after transplantation or if diabetes was reported in their case report forms. NODAT
excluded those patients with diabetes previous to transplant
doi:10.1371/journal.pone.0164443.t001
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significant results were found in sample B. Among those individuals with less than 3 immuno-
suppressant drugs, sample A had lower prescription of glucocorticoids than sample B, probably
contributing to explain the differences of weight gain observedbetween both samples (S4 and
S5 Tables).
10%WG one year after transplantation. In both samples A and B, those gaining10%
of weight had lower BMI at baseline and higher BMI 12 months after transplantation com-
pared to those gaining<10% (Tables 1 and 2). The prevalence of overweight and obese was
lower at baseline and higher at one year after transplantation for10% when compared to
<10%WG. The transplanted organ differed between10% and<10% for both A and B sam-
ples. The kidney was the most prevalent transplanted organ in both groups. The secondmost
prevalent transplanted organ in the10%WG group was the lung while the heart and the liver
were the third most frequently transplanted organs. In the<10%WG group, the liver and the
lung were among the second and the third most frequently transplanted organs. Additionally,
in sample A donors were younger and individuals had higher cholesterol levels at 12 months in
the10%WG group (median: 50 years and 5.0 cholesterol mmol/L, p 0.04 and p 0.01, respec-
tively). In sample B, significant differences were found in the prescribed immunosuppressive
Table 2. Characteristics of Sample B (all and by 10% weight gain one year after transplantation).
Characteristic All wg10%* wg<10%* p-value #
156 42 78
Recipient age at transplantation (years), median (range) 48 (22–68) 47 (26–66) 49 (22–68) 0.4
Recipient men (%) 60.9 59.5 61.5 0.8
Period of follow up (months), median (range) 12 (1–60) 12 (1–60) 12 (1–60) 1
Living donor (%) 11.5 11.9 7.7 0.4
Donor age (years), median (range) 43.5 (10–73) 45 (10–65) 43 (11–69) 0.7
Transplanted organ (%)
kidney 65.4 76.2 60.3 0.03
Liver 23.7 7.1 26.9
Lung 10.9 16.7 12.8
Before transplant
BMI (kg/m2), median (range) 23.4 (15.8–37.3) 22.9 (18.7–33.5) 24.2 (15.8–37.3) 0.06
Overweight (25 kg/m2 BMI >30 kg/m2), % 24.1 14.3 30.8 0.08
Obese (BMI 30 kg/m2), % 10.9 9.5 12.8
At 12 months after transplant
BMI (kg/m2), median (range) 25.2 (16.5–39.3) 26.8 (20.9–39.3) 24.3 (16.5–35.4) 0.0006
Overweight (25 kg/m2 BMI >30 kg/m2), % 35.1 45.2 28.2 0.004
Obese (BMI 30 kg/m2), % 18.5 28.6 14.1
Incidence of NODAT (%) 28.8 30.9 35.9 0.6
CMV serostatus (%)
Recipient CMV infection (R+) 49.3 30.8 36.1 0.6
Donor CMV infection (D+) 61.5 23.1 15.3
Recipient and Donor CMV infection (R+D+) 27.6 30.8 27.8
Calcineurin inhibitors (%)
TAC 34.6 26.2 47.4 0.02
CSA 65.4 73.8 52.7
wg: weight gain, CMV: Cytomegalovirus, TAC: Tacrolimus, CSA: Cyclosporine, NODAT: New Onset Diabetes After Transplant.
# comparison between wg10% and wg<10%
*at 12 months after transplantation, missing n = 36
doi:10.1371/journal.pone.0164443.t002
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treatments; CSA was highly prescribed in the10%WG when compared to the<10%WG
group (73.8% versus 52.7%, respectively; p 0.02).
Genetic Risk Score analysis
Weighted genetic risk score with GWAS polymorphisms. In samples A and B, w-GRS
ranged from 16 to 40 (SNP group#1) and from 63 to 107 (SNP group#2), respectively. S1 Fig
shows the w-GRS distribution percentage in each sample. The association betweenw-GRS and
BMI over time for sample A is shown on Table 3. w-GRS built from the SNP group#1 was
Fig 1. Percentage of weight gain in Sample A at one year after transplantation by number of immunosuppressant
treatments (cyclosporine, tacrolimus, glucocorticoids, azatioprine and/or mycophenolate).
doi:10.1371/journal.pone.0164443.g001
Table 3. Weighted Genetic Risk Scores from GWAS SNPs and their associations with BMI in Sample A.
n Effect on BMI per additional risk allele [CI 95%] p-value* E. Var (%)
SNP group#1
All population 881 0.16 [0.11–0.23] p<0.008 1.46
Age [18–54] years 444 0.10 [0.01–0.17] 0.08 0.56
Age > 54 years 437 0.23 [0.14–0.32] p<0.008 2.74
SNP group#2
All population 854 0.11 [0.08–0.15] p<0.008 2.08
Age [18–54] years 452 0.08 [0.03–0.13] p<0.008 1.10
Age > 54 years 426 0.13 [0.07–0.19] p<0.008 2.90
E. Var: Explained Variability
CI: Confidence Interval
SNP: Single Nucleotide Polymorphism
BMI: Body Mass Index
* p-value corrected by multiple test
doi:10.1371/journal.pone.0164443.t003
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significantly associated with BMI, showing a 0.16 BMI units increase per additional risk allele
and an explained variability of 1.46%.When stratified by the median of age (w-GRSage
p = 0.001 and p = 0.02 for SNP group#1 and #2, respectively) individuals older than 54 years
old had 0.23 BMI unit increase per additional risk allele and an explained BMI variability of
2.74% whereas those at 54 years or younger showed a trend of 0.10 units increase and 0.56% of
explained BMI variability after multiple test correction (p = 0.08). For SNP group#2, the effect
was slightly lower (0.11 units of BMI per risk allele increase, explained variability of 2.08%).
These results could be partially replicated in sample B (Table 4) for SNP group#1 with an effect
of 0.20 BMI units per risk allele increase and explained variability of 2.40%. Analysis stratified
by sex (w-GRSsex, p = 0.03 for SNP group#1) showed no significant associations after multi-
ple test correction (Table 4). Additionally, a significant interaction betweenw-GRS and organ
(i.e. kidney/non kidney) was found for sample B and SNP group#1 (n = 83, p-value 0.04) show-
ing a slightly higher effect (0.30 units of BMI per risk allele increase) in kidney transplanted
individuals when compared to the overall 0.20 units. When combining samples A and B, BMI
increased by 0.14 [0.09–0.19] and 0.11 [0.07–0.15] units per additional risk allele in SNP
group#1 and #2, respectively, p-values<0.001).
Weighted genetic risk score in Candidate Gene polymorphisms(SNP group#3). No
association of w-GRS from SNP group#3 and BMI was found in sample A whereas an increase
of 0.05 units of BMI per additional risk allele was found in sample B (p-value 0.048) with an
explained BMI variability of 1.72% (S6 Table). In addition, in sample B, when SNPs group#3
and #1 were combined (49 SNPs excluding repeated SNPs) a significant association with BMI
was found with an increase of 0.16 BMI units per additional risk allele and an explained BMI
variability of 4.1% (p-value: 0.001) (S7 Table). The w-GRS from group SNP#3 in the combined
A and B sample showed an effect of 0.01 kg/m2 per additional risk allele (p-value 0.04).
Prediction of 10%WG one year after transplantation. For the models in which the w-
GRS was significantly associated with BMI, we evaluated the ability of the model to discrimi-
nate between gainers of10% of weight and those who gained<10% the first year after trans-
plantation. In sample A, a model adjusted by clinical covariates (i.e. age, sex,
immunosuppressant treatment (tacrolimus and/or cyclosporine), baseline BMI and trans-
planted organ) as well as genetic factors (i.e. SNP group#1) performed better than a model
adjusted only by clinical covariates (LRT-p: 0.0004). The predictive value for gaining 10% or
Table 4. Weighted Genetic Risk Scores from GWAS SNPs and their associations with BMI in Sample B.
n Effect on BMI per additional risk allele [CI 95%] p-value E. Var (%)
SNP group#1
All population 124 0.20 [0.07–0.35] 0.02 2.40
Men 82 0.14 [-0.01–0.31] 0.05* n.c
Women 61 0.28 [-0.05–0.63] 0.05 n.c
SNP group#2
All population 117 0.02 [-0.08–0.11] 0.28 n.c
Men 69 -0.03 [-0.18–0.07] 0.33 n.c
Women 53 0.04 [-0.16–0.25] 0.34 n.c
E. Var: Explained Variability
CI: Confidence Interval
BMI: Body Mass Index
SNP: Single Nucleotide Polymorphism
n.c: not calculated because of non significant association and/or low sample size
* values obtained with 100 bootstraps
doi:10.1371/journal.pone.0164443.t004
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more weight when including SNP group#1 in the model resulted in an AUROC of 0.74, a speci-
ficity of 0.61, a sensitivity of 0.77 and an accuracy of 0.65, whereas the model without genetic
components had 0.66, 0.59, 0.66 and 0.61 of AUROC, specificity, sensitivity and accuracy,
respectively (Table 5). Similarly, the genetic model including SNP group#2, performed better
(LRT-p: 0.008) and had higher AUROC (0.80) than the non genetic model (AUROC non
genetic: 0.66). Similarly, for sample B, the genetic model including clinical covariates and SNP
group#1 was significantly different from the clinical model, (LRT-p: 0.04) had an AUROC of
0.89 and a specificity, sensitivity and accuracy of 0.78, 0.88 and 0.81, respectively (Table 5). The
prediction performance of the genetic model compared to the non-genetic one was signifi-
cantly improved as shown by the IDI score. A statistically significant IDI (p<0.01, sample A,
SNP group#2, Table 5) means a significant improvement of the genetic model prediction, by
increasing the average of sensitivity and one minus specificity of the model. The lowest NNG
in order to detect one misclassified case of10% weight increase one year after transplantation
(Table 5) was 6 (obtained for sample B, SNP group#1). In sample A, the NNG was 13 for SNP
group#2 and 24 for SNP group#1.
Discussion
To our knowledge, this is the first study examining the association of clinical and genetic risk
scores withWG in SOT patients. Our results showed that, in transplanted populations, previ-
ously GWAS-BMI related SNPs in general populations, were associated with BMI when com-
bined in w-GRS. These results could be partly replicated in a second sample (i.e. sample B).
The influence of weighted score including SNP group#1 on BMI has been extensively repli-
cated in several general populations from different ethnicities [29–32]. This is the first study
evaluating the effect of these polymorphisms on BMI in SOT recipients (kidney, liver, lung,
heart, or multi-organ) andWG, with positive results being found in both samples. SNPs
group#2 was recently published [27] and contained a higher number of SNPs (including those
from SNP group# 1 except of 2 SNPs). However, significant results were found only in sample
A. The non replication using SNPs group#2 in sample B could be attributed either to no effect
Table 5. Comparison of genetic versus non-genetic model for 10% weight gain prediction at one year after transplantation.
AUROC [95% CI] Specificity Sensitivity Accuracy LRT-p IDI [95% CI]* NNG
Sample A SNP group#1
non genetic model 0.66 [0.58–0.72] 0.59 0.66 0.61 0.0004 0.08 [0.06–0.10] 24
genetic model 0.74 [0.70–0.83] 0.61 0.77 0.65
SNP group#2
non genetic model 0.66 [0.54–0.69] 0.65 0.62 0.64 0.008 0.17 [0.14–0.20] 13
genetic model 0.80 [0.71–0.84] 0.70 0.77 0.72
Sample B SNP group#1
non genetic model 0.67 [0.61–0.88] 0.55 0.76 0.63 0.04 0.36 [0.28–0.45] 6
genetic model 0.89 [0.79–0.97] 0.78 0.88 0.81
AUROC: Area Under the Receiver Operating Characteristic Curve
IDI: Integrated Discrimination Improvement
NNG: Number Needed to Genotype
LRT: Likelihood Ratio tests
SNP: Single Nucleotide Polymorphism
CI: Confidence Interval
*p-value < 0.01
doi:10.1371/journal.pone.0164443.t005
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at all or to the low number of patients in the latter sample and the large number of polymor-
phisms in group#2, each one of small effect size, thus necessitating large sample sizes in order
to observe an effect [48].
In addition, an exploratory analysis of 19 polymorphisms combined in a w-GRS (SNP
group#3) showed an association with BMI in sample B. These variants were selected from a
microarray study examining subcutaneous gene expression which was correlated with weight
change in kidney transplant recipients [25]. These findings should be considered as prelimi-
nary as they were not further replicated nor corrected for multiple test. In sample B individuals
were younger, had lower percentage of living donors and gainedmore weight after the first
year of transplant compared to sample A. Young age, low BMI at baseline and deceaseddonors
increase the risk of gaining weight, as previously described in the literature [15, 49]. Adding
SNP group#3 to SNP group#1 resulted in an increased explained BMI variability of 4.1%. How-
ever, when all SNPs were combined (i.e. SNP group#2 and SNP group#3), no significant results
were found, probably due to the low effect and sample size.
In a second step, we showed that a combination of extensive genetic factors and clinical data
predicts better a 10%WG after the first year of treatment than considering the model with clin-
ical data alone, increasing AUROC and accuracy. When examining genetic factors in sample
A, several polymorphisms were significantly associatedwith 10%WG one year post-transplant.
Interestingly, when looking at SNPs individually, onlyMC4R (rs571312, rs6567160) and
SEC16B (rs543874) remained significant in both SNP group#1 and #2 analyses.MC4R is one of
the most common genetic causes of obesity and this gene participates in appetite regulation
and energy balance [50]. SEC16B has been associated with obesity-related phenotypes but the
mechanism behind remains unknown. In sample B, 4 SNPs in or nearMTIF3, ETV5,GNPDA2
and FAIM2 gene regions (rs1006353, rs7647305, rs10938397 and rs7138803)were associated
with 10%WG one year post-transplant (S8–S10 Tables). Most of these gene functions are not
clear yet. ETV5modulates circulating glucocorticoids levels [51] and GNPDA2 regulates meta-
bolic pathways leading to insulin resistance [52]. Interestingly, the best group of polymor-
phisms predicting 10%WG at 12 months post-transplant was SNP group#2 (n = 97 SNPs) for
sample A and SNP group#1 (n = 32 SNPs) for sample B. This could be tentatively explained by
the fact that a higher sample size (i.e. sample A) is necessary to demonstrate the association
with larger set of SNPs (i.e. SNP group#2). Finally, only the SNP group#1 was associated with
BMI change over time in both samples A and B.
In samples A and B, the mean of WG after one year post-transplant is 3.5% and 6.3%,
respectively, i.e. much lower than the 10%mean value described in the literature [15]. It should
be noted that a solid consensus does not exist yet regardingWG after the first year post-trans-
plantation; a mean of 10% has been describedbut a range from 3.5 to 10 kg as well. AWG of
10 kg over the first year following kidney [12, 13, 53] liver [14] and cardiac [10] transplantation
as described in some studies would correspond to an increase of 14% of weight in our samples
(considering a mean baseline weight in sample A and B of 71 kg and 69.5 kg, respectively)
which would be much higher than theWG mean in our samples.
Some limitations of the present study should be acknowledged. These results can only be
extrapolated to Caucasians.We could not obtain all genotypes, in particular those from the SNP
group#3 and possible co-medications influencingweight in addition to the immunosuppressant
treatment were not reported and/or considered. Finally, sample B size was small and other repli-
cation in larger cohorts should be tested. However, both samples were obtained from naturalistic
setting studies, which should represent the real cases in clinical practice. Further studies should
analyze whether graft rejection in less than one year would influenceweight gain (out of the
scope of the present study). Also, further analysis stratified by type of transplanted organ should
be conducted, as weight gain may differ depending on this factor as recently described[54].
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Conclusions
To conclude, this is the first study evaluating extensively the association of w-GRS with BMI
and the influence of clinical and genetic components on10%WG over the first year post
transplant. The results obtained in the present study, showed the importance of integrating
genetic factors in the final model, since they contain predictive information on10%WG.
Genetics of obesity among SOT recipients remains an important issue and will definitely con-
tribute towards treatment personalizing and prediction improvement of WG in these popula-
tions by identifying at risk-individuals.
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